Oncology PracticeFDA approves nivolumab for HCC patientsSeptember 25, 2017GastroenterologyImmuno-oncologyGI OncologyGastrointestinal Cancer
Oncology PracticeCRP may predict survival after immunotherapy for lung cancerSeptember 20, 2017Immuno-oncologyLung CancerImmunotherapy
Oncology PracticeTocilizumab looks promising for corticosteroid refractory anti-PD-1-related adverse eventsSeptember 20, 2017Immuno-oncologyImmunotherapyLung CancerCellular Therapy
Oncology PracticeAdding T-vec might help surmount PD-1 resistance in melanomaSeptember 14, 2017Immuno-oncologyMelanomaImmunotherapy
Oncology PracticeCheckmate 238: Nivolumab bests ipilimumab for resectable stage III or IV melanomaSeptember 11, 2017Immuno-oncologyMelanoma
Oncology PracticePACIFIC: Durvalumab extends PFS in stage 3 NSCLCSeptember 10, 2017Immuno-oncologyLung Cancer
Oncology PracticePembrolizumab, nivolumab linked to 3% rate of neurologic eventsSeptember 5, 2017Immuno-oncologyPatient & Survivor CareHodgkin LymphomaMelanomaLung CancerRenal Cell CarcinomaHead & Neck/Thyroid Cancers
Hematology NewsFDA approves first gene therapy – tisagenlecleucel for ALLAugust 30, 2017ALLLeukemia, Myelodysplasia, TransplantationPediatricsImmuno-oncology
Oncology PracticeAdverse effects of PD-1/PD-L1 inhibitors varied by tumor type in systematic reviewAugust 28, 2017Immuno-oncologyImmunotherapyMelanomaRenal Cell CarcinomaLung Cancer
Oncology PracticeFDA approves nivolumab for metastatic CRCAugust 2, 2017GastroenterologyImmuno-oncologyImmunotherapyGI OncologyGastrointestinal Cancer
Hematology NewsEnasidenib gets FDA approval for AML with IDH2 mutationsAugust 1, 2017AMLLeukemia, Myelodysplasia, TransplantationImmuno-oncology
Oncology PracticeNew SU2C translational team aims to apply CAR T-cell therapy to pancreatic cancerAugust 1, 2017Immuno-oncologyGastroenterologyImmunotherapyGastrointestinal Cancer
Hematology NewsPembrolizumab takes on r/r PMBCLJuly 20, 2017Aggressive LymphomasLymphoma & Plasma Cell DisordersImmuno-oncology
Hematology NewsAvelumab induces response in Hodgkin lymphoma after failed allo-SCTJuly 20, 2017Hodgkin LymphomaLymphoma & Plasma Cell DisordersImmuno-oncology
Hematology NewsIMiD/Anti-CD20 combo induces complete responses in r/r NHLJuly 19, 2017Mantle Cell LymphomaLymphoma & Plasma Cell DisordersAggressive LymphomasImmuno-oncologyFollicular Lymphoma
